This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Boehringer Ingelheim And Eli Lilly And Company Announce Positive Top-line Pivotal Phase III Data Results For Empagliflozin

CONTACT: Catherine LondonAssociate Director, Communications and Public RelationsBoehringer Ingelheim Pharmaceuticals, Inc.Email: usnews@boehringer-ingelheim.comPhone: (203) 798-4638

Tammy HullCommunications ManagerLilly DiabetesEmail: hullta@lilly.comPhone: (317) 651-9116

1. Data on file, Boehringer Ingelheim Pharma GmbH &Co KG.  2. Woerle HJ, Ferrannini E, Berk A, et al. Safety and Efficacy of Empagliflozin as Monotherapy or Add-On to Metformin in a 78-Week Open-Label Extension Study in Patients with Type 2 Diabetes. Abstract #49-LB. Presented at the American Diabetes Association's (ADA's) 72nd Scientific Sessions®. June 8-12, Philadelphia, PA.  3. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.  4. International Diabetes Federation. IDF Diabetes Atlas Poster. 2012 Update. 2012 (5th Edition).  5. International Diabetes Federation. IDF Diabetes Atlas, 5th Edition: What is Diabetes? http://www.idf.org/diabetesatlas/5e/what-is-diabetes. Accessed on:  December 18, 2012.

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )    (Logo: http://photos.prnewswire.com/prnh/20110825/DE57898LOGO )

 

SOURCE Eli Lilly and Company; Boehringer Ingelheim

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,276.29 +217.94 1.36%
S&P 500 1,913.85 -58.33 -2.96%
NASDAQ 4,636.1050 -140.4030 -2.94%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs